Stocks Health care BHVN
NYSE · Health careBiohaven Ltd. (BHVN)
It posted a net loss of $542.7M. In fiscal 2025 capital spending exceeded operating cash flow by $610.2M. At September 30, 2026 it held $95.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 29, 2026.
Key facts about Biohaven Ltd.
- Net worth
- Biohaven Ltd. has a market value (market cap) of $2.3B at the latest share price, and shareholders' equity of -$98.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $609.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 29, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Biohaven Ltd.'s next report is expected around March 1, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Biohaven Ltd. does
Biohaven Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker BHVN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$738.8M | -$6.86 | -$610.2M |
| 2024 | n/a | -$846.4M | -$9.28 | -$586.5M |
| 2023 | n/a | -$408.2M | -$5.73 | -$334.8M |
| 2022 | n/a | -$570.3M | -$12.75 | -$303.8M |
| 2022 | n/a | -$213.8M | -$5.43 | -$146.8M |
| 2020 | n/a | -$118.7M | -$3.01 | -$77.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Biohaven Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 29, 2026
- October 29, 2026
- October 22, 2026
- October 15, 2026
- September 10, 2026Other event 8-K
- August 26, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 10, 2026
- August 10, 2026
- August 7, 2026
Insider trades
What the people running Biohaven Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| March 17, 2026 | Mehta KishanDirector | Gave as a gift | 17,342 | - |
| March 17, 2026 | Mehta KishanDirector | Gave as a giftindirect | 17,342 | - |
| January 5, 2026 | Gentile KimberlySVP, Clinical Operations | Exercised options | 3,750 | - |
| January 5, 2026 | Gentile KimberlySVP, Clinical Operations | Shares withheld for tax | 1,956 | $19.4K |
| January 5, 2026 | Coric VladChief Executive Officer, Director | Exercised options | 14,250 | - |
| January 5, 2026 | Coric VladChief Executive Officer, Director | Shares withheld for tax | 7,430 | $73.8K |
| January 5, 2026 | Car BruceChief Scientific Officer | Exercised options | 4,750 | - |
| January 5, 2026 | Car BruceChief Scientific Officer | Shares withheld for tax | 2,381 | $23.6K |
Who owns BHVN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Suvretta Capital Management, LLC13G, passive with 2 related filers | 7.8% | February 13, 2026 |
| JANUS HENDERSON GROUP Ltd.13G, passive | 5.7% | July 8, 2026 |
| Woodline Partners LP13G, passive | 5.1% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 294 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 13,210,585 | +1,988,178 |
| Montanova Capital, LLC | 10,286,937 | 0 |
| Stifel Financial Corp | 9,941,165 | +280 |
| Jupiter Topco LLC | 8,584,675 | new |
| Woodline Partners LP | 7,660,280 | +7,359,891 |
| State Street Corp | 6,947,034 | +328,231 |
| Infinitum Asset Management, LLC | 6,250,000 | 0 |
| D. E. Shaw & Co., Inc. | 4,190,195 | +1,343,002 |
| Aqr Capital Management LLC | 4,150,616 | +2,175,100 |
| Geode Capital Management, LLC | 3,323,190 | +555,427 |
| Fmr LLC | 2,964,630 | +605,583 |
| Royalty Pharma Sub-Manager, LLC | 2,936,507 | 0 |
| Cormorant Asset Management, LP | 2,610,000 | +850,000 |
| Goldman Sachs Group Inc | 2,583,046 | +69,865 |
| UBS Group AG | 2,518,827 | +1,092,400 |
| Vanguard Portfolio Management LLC | 2,488,941 | +209,666 |
| Balyasny Asset Management L.P. | 1,879,734 | -565,682 |
| TCG Crossover Management, LLC | 1,779,952 | -2,851,365 |
| Nuveen, LLC | 1,744,334 | +998,586 |
| Rubric Capital Management LP | 1,721,493 | new |
Insiders
8 insiders reported holding 10,631,053 shares in total, about $161.9M at the last price.
| Holder | Shares |
|---|---|
| Childs John WDirector | 5,653,9045,653,904 held indirectly |
| Coric VladChief Executive Officer, Director | 2,544,514740,546 held indirectly |
| Bailey GregoryDirector | 2,020,071 |
| Buten MatthewChief Financial Officer | 195,652 |
| Gentile KimberlySVP, Clinical Operations | 99,557 |
| Clark George C.VP, Chief Accounting Officer | 86,97820,000 held indirectly |
| Mehta KishanDirector | 22,66217,342 held indirectly |
| Car BruceChief Scientific Officer | 7,715 |
Questions about BHVN
What does Biohaven Ltd. do?
Biohaven Ltd. is a company in the Health care sector, listed on NYSE as BHVN. Its shares trade on NYSE under the ticker BHVN.
What is Biohaven Ltd.'s net worth?
Biohaven Ltd. has a market value (market cap) of $2.3B at the latest share price, and shareholders' equity of -$98.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Biohaven Ltd. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $542.7M.
When did Biohaven Ltd. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 29, 2026. It covers the period to September 30, 2026.
When is Biohaven Ltd.'s next earnings report?
Biohaven Ltd.'s next report is expected around March 1, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare BHVN with
Follow BHVN
Get an email when Biohaven Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Biohaven Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.